Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response in triple-negative breast cancer: A systematic review and meta-analysis

被引:0
|
作者
Sun, Hai-Kuan [1 ]
Jiang, Wen-Long [1 ]
Zhang, Shi-Lei [1 ]
Xu, Peng-Cheng [1 ]
Wei, Li-Min [1 ]
Liu, Jiang-Bo [1 ]
机构
[1] Henan Univ Sci & Technol, Affiliated Hosp 1, Coll Clin Med, Dept Thyroid & Breast Surg, 24 Jinghua Rd, Luoyang 471000, Henan, Peoples R China
来源
WORLD JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 15卷 / 07期
关键词
Breast cancer; Tumor-infiltrating lymphocyte; Neoadjuvant therapy; Treatment response; Systematic review; Meta-analysis; CHEMOTHERAPY; EXPRESSION; CARBOPLATIN; SURVIVAL; IMMUNITY; BENEFIT; TRIAL; BIAS;
D O I
10.5306/wjco.v15.i7.920
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND The association between tumor-infiltrating lymphocyte (TIL) levels and the response to neoadjuvant therapy (NAT) in patients with triple-negative breast cancer (TNBC) remains unclear. AIM To investigate the predictive potential of TIL levels for the response to NAT in TNBC patients. METHODS A systematic search of the National Center for Biotechnology Information PubMed database was performed to collect relevant published literature prior to August 31, 2023. The correlation between TIL levels and the NAT pathologic complete response (pCR) in TNBC patients was assessed using a systematic review and meta-analysis. Subgroup analysis, sensitivity analysis, and publication bias analysis were also conducted. RESULTS A total of 32 studies were included in this meta-analysis. The overall meta-analysis results indicated that the pCR rate after NAT treatment in TNBC patients in the high TIL subgroup was significantly greater than that in patients in the low TIL subgroup (48.0% vs 27.7%) (risk ratio 2.01; 95% confidence interval 1.77-2.29; P < 0.001, I2 = 56%). Subgroup analysis revealed that the between-study heterogeneity originated from differences in study design, TIL level cutoffs, and study populations. Publication bias could have existed in the included studies. The meta-analysis based on different NAT protocols revealed that all TNBC patients with high levels of TILs had a greater rate of pCR after NAT treatment in all protocols (all P <= 0.01), and there was no significant between-protocol difference in the statistics among the different NAT protocols (P = 0.29). Additionally, sensitivity analysis demonstrated that the overall results of the meta-analysis remained consistent when the included studies were individually excluded. CONCLUSION TILs can serve as a predictor of the response to NAT treatment in TNBC patients. TNBC patients with high levels of TILs exhibit a greater NAT pCR rate than those with low levels of TILs, and this predictive capability is consistent across different NAT regimens.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] The prognostic value of the tumor-stroma ratio compared to tumor-infiltrating lymphocytes in triple-negative breast cancer: a review
    Andour, Layla
    Hagenaars, Sophie C.
    Gregus, Barbara
    Tokes, Anna Maria
    Karancsi, Zsofia
    Tollenaar, Rob A. E. M.
    Kroep, Judith R.
    Kulka, Janina
    Mesker, Wilma E.
    VIRCHOWS ARCHIV, 2025, : 427 - 444
  • [32] Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer
    Kuroda, Hajime
    Jamiyan, Tsengelmaa
    Yamaguchi, Rin
    Kakumoto, Akinari
    Abe, Akihito
    Harada, Oi
    Enkhbat, Bayarmaa
    Masunaga, Atsuko
    BREAST CANCER, 2021, 28 (04) : 904 - 914
  • [33] Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer
    Hajime Kuroda
    Tsengelmaa Jamiyan
    Rin Yamaguchi
    Akinari Kakumoto
    Akihito Abe
    Oi Harada
    Bayarmaa Enkhbat
    Atsuko Masunaga
    Breast Cancer, 2021, 28 : 904 - 914
  • [34] Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Triple-Negative Breast Cancer-Reply
    Leon-Ferre, Roberto A.
    Salgado, Roberto
    Jonas, Sarah Flora
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (04): : 337 - 338
  • [35] Tumor-infiltrating lymphocytes in triple negative breast cancer
    Zakhartseva, L. M.
    Yanovytska, M. O.
    PATHOLOGIA, 2020, (03): : 287 - 294
  • [36] Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization
    Sofia Gomez-Macias, Gabriela
    Molinar-Flores, Guillermo
    Lopez-Garcia, Carlos A.
    Santuario-Facio, Sandra
    Decanini-Arcaute, Horacio
    Valero-Elizondo, Javier
    Trevino-Alvarado, Victor
    Ortiz-Lopez, Rocio
    Dono, Antonio
    Esteban-Zubero, Eduardo
    Alatorre-Jimenez, Moises A.
    Villarreal Garza, Cynthia
    Pena-Curiel, Omar
    Cardona-Huerta, Servando
    ONCOLOGY LETTERS, 2020, 20 (05)
  • [37] Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
    Floris, Giuseppe
    Richard, Francois
    Hamy, Anne-Sophie
    Jongen, Lynn
    Wildiers, Hans
    Ardui, Jan
    Punie, Kevin
    Smeets, Ann
    Berteloot, Patrick
    Vergote, Ignace
    De Croze, Diane
    Meseure, Didier
    Salomon, Anne
    Lae, Marick
    Reyal, Fabien
    Biganzoli, Elia
    Neven, Patrick
    Desmedt, Christine
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (02): : 146 - 153
  • [40] Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer
    Han, Eunkyung
    Choi, Hye Yeon
    Kwon, Hyun Jung
    Chung, Yul Ri
    Shin, Hee-Chul
    Kim, Eun-Kyu
    Suh, Koung Jin
    Kim, Se Hyun
    Kim, Jee Hyun
    Park, So Yeon
    BREAST CANCER RESEARCH, 2024, 26 (01)